Find and Pitch Jounalists, Get Your Story Covered

Tags: MDMA ecstasy PTSD therapy humour pharma

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: To fight U.S. tariffs, Canada should suspend U.S. patents on medicines, one expert argues - about 1 month ago STAT+: FDA scolds drugmaker over promotion that touts ‘misleading’ comparison with generics - about 1 month ago STAT+: Pharmalittle: We’re reading about Bavarian Nordic’s mpox shot, a crackdown on Ozempic prescribing and more - 7 months ago STAT+: Pharmalittle: We’re reading about PBM practices, DOJ tussling with Regeneron, and more - 8 months ago STAT+: A Senate bill was touted as a cure for ‘patent thickets.’ Some say the drug industry watered it down - 9 months ago STAT+: Drug wholesaler owners indicted for alleged role in diverting Gilead and J&J HIV medicines - 9 months ago STAT+: Pharmalittle: We’re reading about Europe’s pharma reform, weight-loss meds, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about a liver-drug approval, pharma’s positive outlook, and more - about 1 year ago STAT+: Many costly generic drugs are unavailable at Amazon, Cuban, and other alternative pharmacies - about 1 year ago STAT+: Pharmalittle: We’re reading about state moves on drug pricing, an asthma med for kids and more - about 1 year ago STAT+: Pharmalittle: We’re reading about weight loss drugs, a cell therapy for melanoma, and more - about 1 year ago STAT+: A lawsuit over a controversial Sanofi drug shortage is unexpectedly revived - about 1 year ago STAT+: Pharmalittle: We’re reading about a U.S. vaccine panel, an abortion pill, and much more - about 1 year ago STAT+: Colombia proceeds with plans to issue a compulsory license for an HIV medicine sold by GSK’s ViiV - about 1 year ago STAT+: Diabetes treatments have improperly listed patents that should be removed, analysis finds - about 1 year ago STAT+: Pharmalittle: We’re reading about FDA’s syphillis-drug plan, India’s manufacturer-inspection demands, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - about 1 year ago STAT+: Pharmalittle: Sanofi scraps rare-disease drug deal under FTC pressure; patients regain weight after stopping Lilly’s Zepbound - over 1 year ago STAT+: Pharmalittle: Bluebird’s sickle-cell screwups may prompt a sale; drugmakers raised prices on widely used meds without new clinical evidence - over 1 year ago STAT+: More drug and device patents were invalidated for bad info than those filed by other industries, analysis finds - over 1 year ago STAT+: Pharmalittle: FTC challenges ‘inaccurately or improperly’ listed patents; Elliott builds stake in BioMarin - over 1 year ago STAT+: FTC challenges several big drugmakers over inaccurate or improper patent listings - over 1 year ago STAT+: Pharmalittle: U.S. Senate eyes more policies for regulating PBMs; Novo claims most U.S. Wegovy patients pay less than $25 a month - over 1 year ago STAT+: Pharmalittle: Panel tells FDA that CRISPR sickle cell therapy is safe enough for patients; U.K. is urged to scrap IP demands in trade talks with India - over 1 year ago STAT+: Pharmalittle: Roche buys Roivant bowel disease drug for $7.1 billion; AstraZeneca CEO calls report of imminent retirement ‘fake news’ - over 1 year ago STAT+: Pharmalittle: China arrests an Astellas exec accused of spying; weight-loss drugs are being tested in children - over 1 year ago STAT+: Lilly complains to the U.S. International Trade Commission about unapproved versions of Mounjaro - over 1 year ago STAT+: Pharmalittle: More than 9 in 10 pharmacy techs report drug shortages; Yale and VA strike deal over ketamine patent royalties - over 1 year ago STAT+: Pharmalittle: Lilly sues spas and compounders over ‘unapproved’ Mounjaro; nasal-spray EpiPen alternative suffers setback - over 1 year ago STAT+: Lilly sues compounders, wellness centers and spas over unapproved versions of Mounjaro - over 1 year ago
2	John Timmer Ars Technica Science Wrangler for Ars Technica. The big city Science CommunicationWriting	Science paper piracy site Sci-Hub shares lots of retracted papers - 3 months ago
3	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	UK regulator warns against buying weight-loss medicines without prescription - 3 months ago
4	N. Adam Brown MD MedPage Today Healthcare Strategist/Communicator. Washington, D.C. Healthcarestrategycommunication	Direct-to-Consumer Drugs: Big Pharma's Digital Health Play - 7 months ago
5	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	Antiviral used for mpox no better than placebo, NIH says - 8 months ago
6	Beth Mole Ars Technica Senior Health Reporter @ArsTechnica. microbiologyinfectious diseasespublic health	Buying shady weight loss drugs online is a bad idea, in case you were wondering - 8 months ago CVS ditches common cold meds after FDA advisers say they’re useless - over 1 year ago
7	Katie Palmer STAT News Health tech reporter @statnews. JSK Stanford alum. MA health technologysciencejournalism	Weight loss drugs without a prescription? Study warns it’s a ‘very risky business’ - 8 months ago
8	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Will the real Ozempic please stand up? Lilly, Novo face uphill counterfeit battle - 9 months ago Cutting pills. Rationing insulin. How Americans struggle to pay for drugs. - 12 months ago
9	Deanna Fox, PharmD Pharmacy Times Former journalist. Now comms exec. Capital Region, New York communications	OTC Case Studies, Pain Management - 10 months ago OTC Case Studies: Winter Colds - about 1 year ago
10	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Issues Letters to 6 Companies for Unapproved, Misbranded OTC Analgesic Products - about 1 year ago

Journalists covering Pirated Medicine